Sökning: WFRF:(Frost D)
> (2000-2004) >
Vincristine in chil...
Vincristine in childhood leukaemia : No pharmacokinetic rationale for dose reduction in adolescents
-
- Frost, B.-M. (författare)
- Dept. of Women's/Children's Health, University Children's Hospital, Uppsala, Sweden
-
- Lonnerholm, G. (författare)
- Lönnerholm, G., Dept. of Women's/Children's Health, University Children's Hospital, Uppsala, Sweden, University Children's Hospital, SE-751 85 Uppsala, Sweden
-
- Koopmans, P. (författare)
- Department of Pharmacy, University Hospital, Groningen, Netherlands
-
visa fler...
-
- Abrahamsson, J. (författare)
- University Children's Hospital, Uppsala, Sweden, Queen Silvia Children's Hospital, Gothenburg, Sweden
-
- Behrendtz, M. (författare)
- Östergötlands Läns Landsting,Barn- och ungdomsmedicinska kliniken US
-
- Castor, A. (författare)
- Department of Paediatrics, University Hospital, Lund, Sweden
-
- Forestier, E. (författare)
- Department of Clinical Sciences, Paediatrics, University of Umeå, Umeå, Sweden
-
- Uges, D.R.A. (författare)
- Department of Pharmacy, University Hospital, Groningen, Netherlands
-
- De, Graaf S.S.N. (författare)
- De Graaf, S.S.N., University Children's Hospital, Nijmegen, Netherlands, Beatrix Children's Hospital, Groningen, Netherlands
-
visa färre...
-
Dept of Women's/Children's Health, University Children's Hospital, Uppsala, Sweden Lönnerholm, G., Dept. of Women's/Children's Health, University Children's Hospital, Uppsala, Sweden, University Children's Hospital, SE-751 85 Uppsala, Sweden (creator_code:org_t)
- 2003
- 2003
- Engelska.
-
Ingår i: Acta Paediatrica. - 0803-5253 .- 1651-2227. ; 92:5, s. 551-557
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aim: To investigate whether there is any pharmacokinetic rationale for the common practice of administering vincristine to adolescents at relatively lower doses than those to younger children. Methods: A total of 98 children, aged 1.3-17.3 y, with acute lymphoblastic leukaemia (ALL) were studied on day 1 of induction therapy. Plasma samples were drawn before and 10, 30, 360 and 1380 min after injection of vincristine 2.0 mg/m2 (maximum dose 2.0 mg) and analysed by high-performance liquid chromatography. Results: The median value (and range) for distribution half-life was 6.4 min (0.8-11.8), elimination half-life 1014 min (258-2570), volume of distribution 445 L/m 2 (137-1241) and total body clearance 362 ml/min/m2 (134-2553). No correlation was found between age and any of these pharmacokinetic parameters. The area under the concentration time curve (AUC) was significantly correlated to age (p = 0.002, ?-0.31), as expected from the dosage of vincristine. The lower AUC in children with a body surface area > 1 m2, which is reached at 8-9 y of age, indicates that they received a less intense treatment because of the capping of the vincristine dose at 2.0 mg. Conclusions: Vincristine pharmacokinetics were not age dependent in this paediatric population. Thus, we found no pharmacokinetic rationale for dose reduction in adolescents. The common practice of limiting the vincristine dose to 2.0 mg should be carefully reconsidered.
Nyckelord
- Acute lymphoblastic leukaemia
- Children
- Pharmacokinetics
- Vincristine
- NATURAL SCIENCES
- NATURVETENSKAP
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas